Cas:19404-24-1 3-Methyl-1-benzothiophene-5-carboxylic acid manufacturer & supplier

Chemical Name:3-Methyl-1-benzothiophene-5-carboxylic acid

CAS.NO:19404-24-1

Synonyms:3-Methylbenzothiophene-5-carboxylic acid;3-Methyl-benzo<b>thiophen-5-carbonsaeure;3-methylbenzo[b]thiophene-2-carbonyl chloride;3-Methyl-benzo[b]thiophen-2-carbonylchlorid;3-methyl-benzo[b]thiophene-5-carboxylic acid;benzo[b]thiophene-2-carbonyl chloride

Molecular Formula:C₁₀H₈O₂S

Molecular Weight:192.23400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:65.54000

Exact Mass:192.02500

LogP:2.90790

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Methylbenzothiophene-5-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,benzo[b]thiophene-2-carbonyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Methyl-benzo&lt Use and application,b&gt technical grade,usp/ep/jp grade.

Related News: The monthly injection to suppress the virus that causes AIDS was aimed as an alternative to daily pills. 3-Methyl-1-benzothiophene-5-carboxylic acid manufacturer Take penicillin industrial salt and vitamin C as examples. They are the two strategic varieties of chemical raw materials in China, and they are also representatives of severe overcapacity. 3-Methyl-1-benzothiophene-5-carboxylic acid supplier Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers. 3-Methyl-1-benzothiophene-5-carboxylic acid vendor Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology. 3-Methyl-1-benzothiophene-5-carboxylic acid factory “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement.